UNITED THERAPEUTICS Corp
UTHR · XNASCIK 1082554fmd_077A3WEM1Q3N29BM05DYGDVGDMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,599 | 1,725 | 1,628 | 1,449 | 1,483 | 1,686 | 1,936 | 2,328 | 2,877 | 3,183 |
| Cost of revenue | 73 | 106 | 199 | 118 | 108 | 123 | 152 | 258 | 310 | 384 |
| Gross profit | 1,526 | 1,620 | 1,429 | 1,331 | 1,375 | 1,563 | 1,785 | 2,070 | 2,568 | 2,798 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | – |
| Research and development | 148 | 265 | 358 | 1,183 | 358 | 540 | 323 | 408 | 481 | 550 |
| Selling, general and administrative | 317 | 330 | 266 | – | – | 467 | 482 | 477 | 710 | 756 |
| Operating income | 1,062 | 815 | 805 | (188) | 594 | 556 | 980 | 1,185 | 1,377 | 1,493 |
| Interest expense | 4 | 9 | 14 | 44 | 24 | 19 | 32 | 59 | 43 | 20 |
| Interest and investment income | 4 | 11 | 29 | 44 | 29 | 17 | 45 | 163 | 199 | 192 |
| Other non-operating income (expense) | (2) | (45) | (47) | 23 | 45 | 38 | (29) | 89 | 162 | 221 |
| Income before taxes | 1,060 | 770 | 759 | (165) | 639 | 594 | 951 | 1,274 | 1,539 | 1,714 |
| Income tax expense | 347 | 352 | 170 | (61) | 124 | 118 | 223 | 290 | 344 | 379 |
| Net income from continuing operations | 714 | 418 | 589 | (105) | 515 | 476 | 727 | 985 | 1,195 | 1,335 |
| Net income | 714 | 418 | 589 | (105) | – | 476 | 727 | 985 | 1,195 | 1,335 |
| Net income to common shareholders | 714 | 418 | 589 | (105) | 515 | 476 | 727 | – | – | – |